Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Genitourinary 1Dermatologic 1

Conditions

Colorectal Neoplasms 498Rectal Neoplasms 268Colonic Neoplasms 219Pancreatic Neoplasms 190Stomach Neoplasms 183Esophageal Neoplasms 135Neoplasm Metastasis 98Adenocarcinoma Of Esophagus 67Esophageal Squamous Cell Carcinoma 62Carcinoma, Hepatocellular 56Neoplasms 44Cholangiocarcinoma 33Biliary Tract Neoplasms 27Adenocarcinoma 27Anus Neoplasms 26Gastrointestinal Neoplasms 25Gallbladder Neoplasms 22Liver Neoplasms 21Carcinoma, Non-Small-Cell Lung 20Bile Duct Neoplasms 19Parkinson Disease 4, Autosomal Dominant Lewy Body 16Ovarian Neoplasms 11Digestive System Neoplasms 10Colorectal Cancer Metastatic 10Carcinoma, Squamous Cell 10Peritoneal Neoplasms 9Breast Neoplasms 9Anal Canal Carcinoma 9Lung Neoplasms 8Head and Neck Neoplasms 8

Interventions

Irinotecan 4Gemcitabine 4130-nm albumin-bound paclitaxel 4napabucasin 3Cyclophosphamide 3Bevacizumab 3Albumin-Bound Paclitaxel 3selpercatinib 2pembrolizumab 2cobimetinib 2Sunitinib 2Sorafenib 2Pemetrexed 2Paclitaxel 2Leucovorin 2Fluorouracil 2Drug Therapy 2Chemoradiotherapy 2Cetuximab 2Aspirin 2Ascorbic Acid 2trametinib 1repotrectinib 1pralsetinib 1osimertinib 1lutetium Lu 177 dotatate 1linifanib 1guadecitabine 1golotimod 1genexol-PM 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms by Site × Fluorouracil × Gastrointestinal × Clear all
NCT02753127 2023-11-15

CanStem303C

Sumitomo Pharma America, Inc.

Phase 3 Completed
1,253 enrolled 18 charts
Gastrointestinal

Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Rectal Diseases, Colorectal Neoplasms

NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Sumitomo Pharma America, Inc.

Phase 1 Completed
7 enrolled
Gastrointestinal

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡